Novo Nordisk: Catch That Falling Knife

Company Overview - Novo Nordisk has experienced a significant decline, with its market cap dropping below $200 billion, down from a previous valuation exceeding $600 billion, indicating a more than 20% decrease [2]. Market Competition - The company is facing intensified competition in the GLP-1 market, which has contributed to its declining valuation [2]. Investment Strategy - The Value Portfolio focuses on building retirement portfolios through a fact-based research strategy, which includes thorough analysis of 10Ks, analyst commentary, market reports, and investor presentations [2].